Journal
JOURNAL OF ENDOCRINOLOGY AND METABOLISM
Volume 9, Issue 6, Pages 203-204Publisher
ELMER PRESS INC
DOI: 10.14740/jem627
Keywords
Mitochondrial diabetes; SGLT2 inhibitor; Empagliflozin
Categories
Ask authors/readers for more resources
Recent animal studies have suggested that sodium-glucose co-transporter 2 (SGLT2) inhibitors have mitochondrial and cardiorenal protective effects. Herein we report the case of mitochondrial diabetes successfully treated with an SGLT2 inhibitor empagliflozin. Although the underlying mechanisms have still not been completely investigated, SGLT2 inhibitors may improve mitochondria' function, suppress oxidative stress and restore autophagy. SGLT2 inhibitors could be a treatment option for patients with mitochondrial diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available